Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge-Reference-Cited by-同舟云学术

Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge

Published:2024-01-01 Issue:1 Volume:6 Page:
ISSN:2638-616X
Container-title:Radiology: Imaging Cancer
language:en
Short-container-title:Radiology: Imaging Cancer

Author:

Li Wen^ORCID,Partridge Savannah C.^ORCID,Newitt David C.^ORCID,Steingrimsson Jon,Marques Helga S.,Bolan Patrick J.^ORCID,Hirano Michael,Bearce Benjamin Aaron,Kalpathy-Cramer Jayashree^ORCID,Boss Michael A.^ORCID,Teng Xinzhi,Zhang Jiang^ORCID,Cai Jing,Kontos Despina^ORCID,Cohen Eric A.^ORCID,Mankowski Walter C.,Liu Michael,Ha Richard,Pellicer-Valero Oscar J.,Maier-Hein Klaus,Rabinovici-Cohen Simona,Tlusty Tal,Ozery-Flato Michal^ORCID,Parekh Vishwa S.^ORCID,Jacobs Michael A.,Yan Ran,Sung Kyunghyun^ORCID,Kazerouni Anum S.^ORCID,DiCarlo Julie C.,Yankeelov Thomas E.^ORCID,Chenevert Thomas L.^ORCID,Hylton Nola M.^ORCID

Funder

National Institutes of Health

Defense Advanced Research Projects Agency

Cancer Prevention and Research Institute of Texas

Publisher

Radiological Society of North America (RSNA)

Link

http://pubs.rsna.org/doi/pdf/10.1148/rycan.230033

Reference18 articles.

1. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial

2. Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial

3. Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial